



p53-Therapeutics, Inc. Announces New additions to the Executive Management Team

And completes company's relocation to Providence, RI

[Providence, Rhode Island, May 7, 2026] – p53-Therapeutics, a biotech company developing a new class of small molecule cancer therapeutics, today announced the addition of two new Leaders. The Company has established global headquarters, laboratory facilities, and collaborations within the state, including partnerships with academic centers and hospitals, and to build a Rhode Island-based life sciences workforce to bring hope to patients with cancer **and has added two key hires to the Executive Team.**




Bradley J. Sander
Chief Executive Officer

Bradley Sander is an accomplished executive, entrepreneur, and strategic operator with a track record of scaling companies, driving revenue growth, and maximizing enterprise value. He brings extensive experience across business development, product development, marketing, sales, and operations, with a focus on executing strategies to deliver measurable results. He has built and scaled revenue platforms across technology and connected health

and has worked extensively with private equity and venture-backed companies on growth initiatives, operational improvement, and commercialization. His experience includes Executive roles at Disney, and At&t aligning capital deployment with revenue milestones, improving cost efficiency, and building infrastructure to support expansion. He has relevant experience in Fintech, Robotics and Artificial Intelligence and can collaboratively define growth strategies with a focus on translating growth initiatives into measurable financial outcomes.

When reflecting on what excites him the most about the p53 opportunity, Bradley stated: *"I'm excited for the opportunity to help scale the company and drive growth by building a disciplined operational and commercial foundation and secure meaningful Partnerships required for long term success."*



Emile Youssef, MD, PhD
Chief Medical Officer

Dr. Emile Youssef is a physician-scientist and biotechnology executive with more than 30 years of global experience across academia, pharmaceutical companies, biotechnology organizations, and contract research organizations. He earned his MD from Cairo University, a PhD in Molecular Oncology, completed postdoctoral training at The University of Texas MD Anderson Cancer Center, and holds an Advanced Oncology Diploma from Osaka City University. Throughout his career, Dr. Youssef has held senior leadership positions at leading

organizations including Novartis, Eisai, Celgene, Bayer, Worldwide Clinical Trials, Oryn Therapeutics, and Tosk. His expertise spans oncology, hematology, immuno-oncology, cell and gene therapy, translational medicine, clinical development, and medical affairs. Dr. Youssef has extensive experience working with the U.S. Food and Drug Administration and other global regulatory agencies, providing strategic leadership for regulatory interactions and contributing to numerous Investigational New Drug (IND) submissions and development programs. His unique background across academia, industry, biotechnology, and CRO environments enables him to bridge scientific innovation with successful clinical and regulatory execution. A published author and recognized scientific leader, Dr. Youssef has contributed to high-impact peer-reviewed research in immuno-oncology, cell and gene therapy, precision medicine, pharmacovigilance, and cancer drug development. He remains actively engaged in advancing oncology research and clinical innovation through scientific publications and international collaborations. As Chief Medical Officer, Dr. Youssef leads the company's medical and clinical strategy, supporting the advancement of innovative therapies and fostering scientific excellence across the organization.



Dr. Youssef said *"I am excited to join the organization and contribute to its next phase of growth and innovation. I look forward to working with our talented team to advance transformative therapies and create meaningful impact for patients worldwide"*

The Scientific Founder of p53-Therapeutics, **Wafik S. El-Deiry, M.D., Ph.D., FACP**, Founding Director of the Legorreta Cancer Center at Brown University commented on the two new additions to p53 and company relocation:

"We are very pleased to welcome both Bradley Sander as CEO and Emile Youssef as CMO to the p53 organization. Bradley's business leadership and experience scaling organizations will be instrumental as we advance our growth strategy and strengthen the Company for its next phase. Emile brings a wealth of medical and clinical leadership experience as we advance our translational mission with focus and discipline."

"I am happy to see the company laboratory facility and global headquarters of p53-Therapeutics here in Rhode Island within the vibrant and growing biotech ecosystem. There are good opportunities for collaboration and local talent in New England. Rhode Island is a perfect location to have that global impact."



About p53-Therapeutics, Inc.:

The company's two lead programs, small molecules targeting cancers characterized by *TP53* mutations, are currently being evaluated in Investigational New Drug (IND)-enabling studies. p53-Therapeutics was awarded funding through the Rhode Island New Business Attraction Program to support IND-enabling studies and to facilitate its move to the Rhode Island. The award, provided through the Rhode Island Life Science Hub (RILSH), offers financial support for life sciences companies establishing a presence in Rhode Island. RILSH was established by Rhode Island Governor Daniel McKee and Speaker of the House of Representatives Joseph Shekarchi, in 2023 with a \$45 million investment in the life sciences, and a mandate to create business development opportunities for companies, and develop much-needed wet lab incubator spaces. p53-Therapeutics is a **foundational tenant at Ocean State Labs, powered by Portal Innovations**. The company has laboratory space and office space for its workforce and looks forward to becoming part of the vibrant life sciences ecosystem in Rhode Island. The company is collaborating with Provid Pharmaceuticals for large scale drug synthesis as well as numerous analogs of lead compounds in the p53-Therapeutics pipeline.

p53-Therapeutics, Inc. is developing a new class of small molecule cancer therapeutics to effectively bypass mutations in the p53 tumor suppressor gene to treat patients with cancer. *TP53* mutations occur frequently across tumor types. *TP53* is mutated in most human cancers and at an even higher frequency among difficult to treat cancers and in patients that fail first-line therapies. Particularly high mutation rates occur in head and neck, ovarian, colorectal, lung and brain cancer, among others. P53-Therapeutics uses a novel approach with candidate drugs that biochemically and functionally replace this most important cancer suppressor to address therapy resistance in the clinic. The Company is developing molecules to target a broad range of p53-mutated cancers based on compelling pre-clinical safety, efficacy and biomarker data with line of sight to IND filing and strong IP position.